Merck Patent Gmbh

Amgen Research (munich) Gmbh

Micromet Ag

Amgen Research Gmbh

Klaus Brischwein

Peter Kufer

Tobias Raum

Andreas Wolf

Sonja Offner

Birgit Kohleisen

Patrick A Baeuerle

Patrick Bäuerle

Meera Berry

Ulla Lenkkeri-Schütz

Sabine Raab

Otmar Pfaff

Ulrike Dau

Michael Zuehlsdorf

Karin Groll

Juergen Reindl

Frederic Christian Pipp

Heinrich Lannert

Axel Hoffmann

Ulla Lenkkeri-Schutz

Patrick Bauerle

Jürgen Reindl

The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.

Anti-alpha-V integrin antibody for the treatment of prostate cancer

The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

Pharmaceutical composition comprising a bispecific antibody for EpCAM

Growing community of inventors

Munich, Germany

Klaus Brischwein